THE MD-224 DIARIES

Proteolysis-targeting chimeras (PROTACs) and molecular glue degraders (MGDs) are by far the most maturely created TPD methods. In this particular critique, we concentrate on each preclinical experiments and clinical trials to provide a comprehensive summary of the security and scientific efficiency of PROTACs and MGDs in hematologic malignancies in